Trending: Moderna, Merck Say Cancer Vaccine and Keytruda Fight Melanoma
December 13 2022 - 02:33PM
Dow Jones News
14:04 ET -- Moderna Inc. and Merck & Co. Inc. are two of the
most talked about companies in the U.S. across all news items in
the last 12 hours, according to Factiva data. A customized Moderna
cancer vaccine combined with Merck's immunotherapy cancer drug
Keytruda helped ward off the recurrence of the skin cancer melanoma
after surgery in patients in a mid-stage clinical trial, the
companies said. The combination cut patients' risk of relapse or
death by about 44%, versus Keytruda alone, in the 150-volunteer
study. The results suggest promise for an emerging but unproven
class of vaccines that aim to treat diseases rather than prevent
infections like typical shots. Moderna and Merck plan to run a
larger study to confirm the combination's safety and efficacy next
year. The companies said they will also test the combination in
other types of cancers. Dow Jones & Co. owns
Factiva.(jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
December 13, 2022 14:18 ET (19:18 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024